微芯生物(688321.SH)附属与百奥赛图(02315)子公司签署关于YH008的独家许可协议

智通财经2023-02-27

智通财经APP讯，微芯生物(688321.SH)公告，公司控股子公司成都微芯新域生物技术有限公司(“微芯新域”)与百奥赛图(北京)医药科技股份有限公司(“百奥赛图”)全资子公司祐和医药科技(北京)有限公司(“祐和医药”)就双特异抗体新药YH008(“YH008”)签署《独家许可协议》，微芯新域将获得祐和医药YH008在大中华区(包括中国香港、中国澳门和中国台湾，“授权区域”)的研发、生产和商业化的...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2314537237?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2023-02-27 18:48","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2314537237","market":"sh","top_or_hot":-1,"title":"微芯生物(688321.SH)附属与百奥赛图(02315)子公司签署关于YH008的独家许可协议","media":"智通财经","content":"<div>\n<p>智通财经APP讯，微芯生物(688321.SH)公告，公司控股子公司成都微芯新域生物技术有限公司(“微芯新域”)与百奥赛图(北京)医药科技股份有限公司(“百奥赛图”)全资子公司祐和医药科技(北京)有限公司(“祐和医药”)就双特异抗体新药YH008(“YH008”)签署《独家许可协议》，微芯新域将获得祐和医药YH008在大中华区(包括中国香港、中国澳门和中国台湾，“授权区域”)的研发、生产和商业化的...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/883393.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>微芯生物(688321.SH)附属与百奥赛图(02315)子公司签署关于YH008的独家许可协议</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n微芯生物(688321.SH)附属与百奥赛图(02315)子公司签署关于YH008的独家许可协议\n</h2>\n\n<h4 class=\"meta\">\n\n\n2023-02-27 18:48 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/883393.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP讯，微芯生物(688321.SH)公告，公司控股子公司成都微芯新域生物技术有限公司(“微芯新域”)与百奥赛图(北京)医药科技股份有限公司(“百奥赛图”)全资子公司祐和医药科技(北京)有限公司(“祐和医药”)就双特异抗体新药YH008(“YH008”)签署《独家许可协议》，微芯新域将获得祐和医药YH008在大中华区(包括中国香港、中国澳门和中国台湾，“授权区域”)的研发、生产和商业化的...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/883393.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1161","symbol_name":"生物科技","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/883393.html","article_id":"2314537237","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2314537237","pubTimestamp":1677494932,"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP讯，微芯生物 公告，公司控股子公司成都微芯新域生物技术有限公司与百奥赛图(北京)医药科技股份有限公司全资子公司祐和医药科技(北京)有限公司就双特异抗体新药YH008签署《独家许可协议》，微芯新域将获得祐和医药YH008在大中华区的研发、生产和商业化的独占许可权益。公告显示，YH008是一款百奥赛图自主研发、同类首创、专有的用于肿瘤免疫治疗的双特异性抗体。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"688321":"微芯生物","BK1161":"生物科技","BK0239":"医药制造","02315":"百奥赛图-B"},"translate_title":"The subsidiary of Microchip Bio (688321. SH) signed an exclusive license agreement on YH008 with the subsidiary of Baiaoseitu (02315)","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"688321":1,"02315":1},"content_text":"智通财经APP讯，微芯生物(688321.SH)公告，公司控股子公司成都微芯新域生物技术有限公司(“微芯新域”)与百奥赛图(北京)医药科技股份有限公司(“百奥赛图”)全资子公司祐和医药科技(北京)有限公司(“祐和医药”)就双特异抗体新药YH008(“YH008”)签署《独家许可协议》，微芯新域将获得祐和医药YH008在大中华区(包括中国香港、中国澳门和中国台湾，“授权区域”)的研发、生产和商业化的独占许可权益。据悉，微芯新域将向祐和医药支付4000万元人民币的首付款和后续不超过3.6亿元人民币的研发里程碑付款、后续不超过1.96亿元人民币的销售里程碑付款及根据年度净销售额在使用期限内支付一定比例的分级特许权使用费。公告显示，YH008是一款百奥赛图自主研发、同类首创、专有的用于肿瘤免疫治疗的双特异性抗体。该产品目前已获得美国FDA IND批准，并已于2022年12月向中国NMPA递交了项目的国内临床试验申请并获受理。","kind":null,"is_publish_news":null,"is_publish_highlight":null,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"claudebot","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2314537237"}